Analyst says he's thrown in the towel on Novo Nordisk after latest setback

Core Insights - Novo Nordisk's recent study indicated that a new drug did not perform as well as a competitor's product, prompting a downgrade from a sell-side analyst for the first time in five years [1] Company Summary - The downgrade reflects concerns over the efficacy of Novo Nordisk's new drug compared to a rival's offering, which may impact investor sentiment and stock performance [1]